Antiarrhythmics Flashcards
Increased Automaticity
With an arrhythmia from such a mechanism, the goal of the AAD is to lower the maximum frequency at which cardiac APs can occur by:
1. Reducing slope of spontaneous phase 4 depolarization.
2. Prolonging the effective refractory period by:
Making the diastolic potential more negative
Making the threshold potential less negative therefore increasing threshold
Tachyarrhythmias
Mechanisms:
- Increased automaticity of pacemaker and non-pacemaker cells
- Reenterant pathways
- Triggered activity
Antiarrythmic Drugs (AADs) work by interrupting one or more of these mechanisms!
Re-Entrant Pathways
The time to complete the circuit must be greater than the effective refractory period otherwise the arrhythmia will not propagate
A: two pathways that flow down = normal situation
B: beta pathway is blocked/ unidirectional block; tries to go down beta pathway, but cannot so it goes back up and if alpha pathway is still in refractory period, it cannot form a reentry circuit
C: alpha pathway is blocked
D: If the beta pathway is slow it can allow enough time for the alpha pathway to repolarize and then it can propagate the arrhythmia
Re-Entrant Pathways: Mechanism
With an arrhythmia from such a mechanism, two conditions must be met:
Unidirectional block
An area of slowed conduction
AADs interrupt the arrhythmia by:
Prolonging the tissue refractory period
Further slowing of conduction within the already “slowed” area
Suppressing premature beats which initiate reentry
Triggered Activity
With an arrhythmia from such a mechanism, oscillations in the membrane voltage occur known as early afterdeopolarizations (EADs) and delayed afterdepolarizations (DADs).
AADs interrupt the arrhythmia by:
- Suppression of EADs by shortening of the AP and increasing the period of repolarization which prolongs the QT interval
- Suppression of DADs by correcting conditions of calcium overload
A Major Adverse Effect of Many AADs
Most are pro-arrhythmic
QT prolongation primarily by classes IA, IC, III
Prolongation of QT: AP is lengthening (phases 2 and 3); EADs trigger this disorder (Torsade de Pointes)
Vaughan-Williams Classification of Antiarrhythmic Drugs
Class I: (IA, IB, IC): Sodium-channel blockers
Class II: Beta-blockers
Class III: Potassium-channel blockers
Class IV: Calcium-channel blockers
Other Antiarrhythmic Drugs
Have no class specification
Adenosine
Digitalis
Magnesium
Class I
Block the fast Na channels
Thus primarily affect Phase 0 depolarization
Divided into 3 categories (IA, IB, IC) based on degree of Na channel blockade and effect on cell’s AP duration.
IB: Mild Na channel blockade, Shortened AP duration
IA: Moderate Na channel blockade, Prolonged AP duration
IC: Marked Na channel blockade, No change in AP duration
Na channel Blockade: IC > IA > IB (CAB)
Class I AP Changes
Class IC: slope is decreased and AP duration is not increased at all
Class IB: mild blockade with short AP duration increase
Class IA: prolongs AP, repolarization, and refractory period which doesn’t allow for the arrhythmias to propagate because the refractory period blocks any propagation
Class I A, B, and C Drugs
Class IA: Procainamide; Disopyramide; Quinidine
Class IB: Lidocaine; Mexiletine
Class IC: Flecainide; Propafenone
Class IA Mechanism
Slow phase 0 depolarization, prolong APs, and slow conduction
Mechanism: moderate fast Na Channel blockade, thus slows Phase 0 depolarization
Effect on Pacemaker Cells (like all Class I agents)
Decreases automaticity by :
Decreased slope of phase 4 depolarization
Raising the threshold potential
Effect on AP of Myocardial Cells:
Decreases reentry by prolongation of AP duration thus slows conduction (this is due to some K+ channel inhibition properties)
Class IA Clinical Use
Uses:
Paroxysmal SVT
Atrial fibrillation/Atrial flutter
Ventricular tachycardia
Rarely prescribed anymore because of drug interactions
Disopyramide
Class IA
Route: po, IV
Adverse effects:
Anti-cholinergic: dry mouth, constipation, urinary retention, exacerbation of glaucoma
QT Prolongation
Procainamide
Class IA
Route: po, IV, IM
Hypotension can occur with IV route
Adverse effects: Fever, rash GI: diarrhea \+ ANA in 80% of pts taking drug 30% develop drug induced lupus QT prolongation, especially in rapid aceylators
Can be used for pregnant women
Procainamide Metabolites
Metabolite: NAPA (N-acetyl procainamide)
Formed in liver by acetylation.
Elevated levels with renal failure or those that are rapid aceylators.
NAPA has the ability to prolong AP duration, but does not affect the slope of phase 4 depolarization in pacemaker cells and does not affect the slope of phase 0 depolarization.
Quinidine
Class IA
Route: po
Excretion: Liver
QT prolongation
Increased mortality in Afib patients! - AVOID
Class IB Mechanism
Mechanism:
Mild Fast Na Channel blockade
Not much effect on normal tissue, preferentially act on diseased or ischemic myocardium
Effect on Pacemaker Cells (like all class I agents)
Decreases automaticity by :
Decreased slope of phase 4 depolarization
Raising the threshold potential
Effect on AP of Myocardial Tissue:
Reduces slope of Phase 0 depolarization and slows conduction velocity, decreases reentry preferentially in diseased tissue
Shortening of Phase 3 repolarization, thus shortening of AP duration in normal myocardium. This may actually predispose to arrhythmias but decreases chance of QT prolongation.